InternationalUSRemember you can easily switch between MIP US and MIP International at any time

Cover Story

  • The great copyright debate

    Activist Lawrence Lessig says the outdated copyright system criminalises a generation and needs fundamental changes. But Eileen McDermott finds that practitioners have serious doubts about his proposals. PLUS: Lessig responds to his critics

Features

Survey

IP Clinic

  • How should I decide which patents not to renew?

    Given the economic situation, my company is looking to cut costs from our IP department and one option is not to renew some of our patent portfolio. Which factors should I consider in deciding which patents not to renew?

Diary

  • Utynam's Heirs

    A monthly column devoted to IP curiosities and controversies, named in honour of John of Utynam - who received the world’s first recorded patent in 1449

Country Updates

profile

Managing IP

ManagingIP

ManagingIP profile

ICYMI: Our report on this week's #SCOTUS ruling in Star Athletica v Varsity Brands https://t.co/Rf3TWplNUrhttps://t.co/TrZ5YcvKQr

Mar 24 2017 01:35 ·  reply ·  retweet ·  favourite
ManagingIP profile

@Oblon_IP @PatentPostGrant Congratulations Scott! #mipawards

Mar 24 2017 01:13 ·  reply ·  retweet ·  favourite
ManagingIP profile

@KellyIPllp Well done to all at the firm!

Mar 24 2017 02:16 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


March 2017

Roundtable: The second medical use challenge – full transcript

Three leading patent specialists discussed one of the most challenging issues in IP at the moment – incentivising new uses for known drugs – at a recent roundtable discussion. The participants were: Jurgen Dressel, head of global patent litigation strategy, Novartis Pharma; Galit Gonen, VP and general counsel for Europe at Teva; and Professor Sir Robin Jacob, former Court of Appeal judge and professor at the Institute of Brand and Innovation Law, University College London



Most read articles

Supplements